Cipla Rises on Strong Q1 and U.S. Hopes

  Published 8 months ago

Cipla's profit beat estimates on strong India sales; U.S. launches expected to drive future growth amid mixed analyst views.

  • Cipla shares have gained 5% since results; 14 brokerages raised price targets, median now at Rs 1,723.5.
  • HSBC sees FY26 dip in gRevlimid sales but expects U.S. drug launches to cushion impact.
  • Goldman cautious on growth, Jefferies sees H2FY27 U.S. launches as key for future momentum.

You might like these

Mahindra Finance Q2 FY26 Surge

Kajaria Q2 FY26 Results: Revenue Up, Margins Rise

CMS Info Systems Rebrands

L&T Wins Zinc Smelter Project from HZL

Groww Raises Minimum Brokerage: What Investors Need to Know

India Clears ₹300B LPG Subsidy Payout

Firstsource Q1 Profit Rises 27%

News that matters the most ⚡